Table 3.
Changes within, and differences between, study groups at week 26 for secondary outcomes not reflecting disease activity when analysed per protocol
| Baseline values | Change at week 26 vs. baseline (95% CI) | |||
|---|---|---|---|---|
| HAQ (range 0–3, best to worse) | Intervention group (n = 29) | 1.1 (0.6) | −0.15 (−0.35, 0.05) | |
| Control group (n = 33) | 1.1 (0.6) | −0.42 (−0.67, 0.16) | ||
| Group difference (95% CI) | −0.26 (−0.59, 0.06) | |||
| RAID (range 0–10, best to worse) | Intervention group (n = 29) | 4.7 (2.2) | −1.31 (−2.31, −0.31) | |
| Control group (N = 33) | 5.5 (1.7) | −1.17 (−2.12, −0.22) | ||
| Group difference (95% CI) | 0.14 (−1.21, 1.49) | |||
| PASS (yes, %) | Intervention group (N = 29) | 41% (12/29) | 28% (5, 50) | |
| Control group (n = 33) | 33% (11/33) | 27% (5, 50) | ||
| Group difference (95% CI) | 0 (−31, 31) | |||
| BMQ‐necessity (range 5–25, with 25 being the highest level of necessity) | Intervention group (n = 29) | 18.7 (4.3) | 0.68 (−1.04, 2.40) | |
| Control group (n = 33) | 19.3 (3.2) | 0.26 (−1.39, 1.96) | ||
| Group difference (95% CI) | 0.39 (−2.73, 1.95) | |||
| BMQ‐concerns (range 5–25, with 25 being the highest level of concerns) | Intervention group (n = 29) | 13.9 (4.8) | −1.14 (−2.82, 0.54) | |
| Control group (n = 33) | 14.3 (3.37) | −0.71 (−1.78, 0.36) | ||
| Group difference (95% CI) | −0.43 (−1.48, 2.34) | |||
| Patient satisfaction (range 0–10, worst to best) | Intervention group (n = 29) | 8.3 (1.9) | 1.00 (0.18, 1.82) | |
| Control group (n = 33) | 8.3 (1.8) | 0.55 (0.04, 2.21) | ||
| Group difference (95% CI) | 0.45 (−1.37, 0.46) | |||
| EQ‐5D (−1 to +1 (best health) | Intervention group (n = 29) | 0.50 (0.32) | 0.05 ([−0.12] – 0.21) | |
| Control group (n = 33) | 0.48 (0.33) | 0.12 ([−0.04] – 0.28) | ||
| Group difference (95% CI) | −0.08 (−0.15, 0.30) | |||
BMQ: Beliefs about Medicines Questionnaire; CI: confidence interval; EQ‐5D: EuroQol‐5D; HAQ: Health assessment questionnaire; PASS: patient acceptable symptom state, RAID: Rheumatoid arthritis impact of disease.